185 related articles for article (PubMed ID: 2828290)
1. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Kanclerz A; Chapman JD
Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
[TBL] [Abstract][Full Text] [Related]
2. Sensitizers and protectors in radiotherapy.
Brown JM
Cancer; 1985 May; 55(9 Suppl):2222-8. PubMed ID: 2983876
[TBL] [Abstract][Full Text] [Related]
3. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
Yu NY; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
[TBL] [Abstract][Full Text] [Related]
5. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
Ono K; Takahashi M; Nishidai T; Dodo Y; Shibamoto Y; Hiraoka M; Yukawa Y; Abe M
Radiat Med; 1984; 2(1):71-5. PubMed ID: 6242712
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitizing effects of misonidazole and SR 2508 on a human melanoma transplanted in nude mice: influence on repair of potentially lethal damage.
Guichard M; Malaise EP
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):465-8. PubMed ID: 6213589
[TBL] [Abstract][Full Text] [Related]
7. Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
Rojas A; Stewart FA; Denekamp J
Br J Cancer; 1983 Jan; 47(1):65-72. PubMed ID: 6295429
[TBL] [Abstract][Full Text] [Related]
8. Sensitizers and protectors in clinical oncology.
Phillips TL
Semin Oncol; 1981 Mar; 8(1):65-82. PubMed ID: 6264627
[No Abstract] [Full Text] [Related]
9. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
Siemann DW
Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
[TBL] [Abstract][Full Text] [Related]
10. Combined radiosensitization and radioprotection for oral cavity tumors: study with an oral cavity tumor model.
Grigsby P; Maruyama Y
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):557-9. PubMed ID: 6286553
[TBL] [Abstract][Full Text] [Related]
11. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
Twentyman PR
Br J Cancer; 1981 Jun; 43(6):745-55. PubMed ID: 6264941
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances in hypoxic cell radiosensitizer].
Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M
Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470
[TBL] [Abstract][Full Text] [Related]
13. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
[TBL] [Abstract][Full Text] [Related]
14. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
Wallen CA; Moore SK; Wheeler KT
Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
Hinchliffe M; McNally NJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.
Hirst DG; Hazlehurst JL; Brown JM
Br J Cancer; 1984 Jan; 49(1):33-42. PubMed ID: 6229264
[TBL] [Abstract][Full Text] [Related]
17. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
Chaplin DJ
Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
[TBL] [Abstract][Full Text] [Related]
18. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Siemann DW; Maddison K; Wolf K
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
[TBL] [Abstract][Full Text] [Related]
20. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Milas L; Ito H; Hunter N
Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
